PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Ogilvy Public Relations

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

GVK BIO Inaugurates its New Research Center - A dedicated Chemistry Research Center for Wyeth Pharma at Hyderabad, India [NYSE: WYE]
GVK BIO Inaugurates its New Research Center


NewswireToday - /newswire/ - Hyderabad, Andhra Pradesh, India, 2007/10/06 - A dedicated Chemistry Research Center for Wyeth Pharma at Hyderabad, India [NYSE: WYE].

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


GVK Biosciences Private Limited (GVK BIO) today inaugurated the GVK BIO Wyeth Hyderabad Chemistry Center, a built-to-suit research center for Wyeth Pharmaceuticals located in Hyderabad. The Research center was inaugurated by Dr. Robert Ruffolo, Ph.D., President, Wyeth Research, in the presence of Mr. David Hopper, the Consul General, United States Consulate, Chennai, Mr. G V Krishna Reddy, Chairman, GVK Group, Mr. D.S.Brar, Chairman, GVK BIO and Mr. G V Sanjay Reddy, Managing Director, GVK BIO.

A team of 200 synthetic chemists and scientists are working on cutting-edge research in this state-of-the-art facility. The facility is equipped with the latest high-end scientific equipment and instrumentation. The GVK BIO Wyeth Hyderabad Chemistry Center, located at Nacharam is comparable to any international research center.

GVK BIO and Wyeth entered into a collaborative research agreement in 2006. Wyeth selected GVK BIO after a global worldwide search for a suitable chemistry partner. GVK BIO was selected for the strength of their management team, research philosophy, and expertise in the area of Synthetic Organic Chemistry. The current activities include the synthesis of reference standards, building blocks, intermediates, analogues, focused libraries and screening libraries. GVK BIO has a proven capability and track record in delivering value-added scientific services on time.

Mr. G V Krishna Reddy, Chairman, GVK Group said “GVK BIO is our group’s first venture outside of Infrastructure. We are happy with the way GVK BIO has grown rapidly to become India’s leading Contract Research Organization”.

Dr. Ruffolo said “Wyeth has a large discovery portfolio resulting in a growing need for strong medicinal chemistry. By working with GVK BIO as a partner, we are able to tap into the huge chemistry talent pool in India and to work globally on a 24-hour basis. This partnership significantly increases our chemistry capacity and complements our already strong in-house synthetic chemistry efforts.”

“Through this Research partnership, Wyeth has given a strong vote of confidence not only to GVK BIO but on a larger platform to India. Based on the success of the current Medicinal Chemistry projects, we look forward to growing our collaboration in other areas” said Mr. D.S.Brar, Chairman, GVK BIO.

Mr. G.V.Sanjay Reddy said, “GVK BIO has made available the best scientific talent for Wyeth. The facility, human resources and equipment reflect high quality of science and productivity levels. The collaboration has been a win-win for both Wyeth and GVK BIO.”

GVK BIO will be responsible for designing synthetic routes for new molecules, carrying out the synthesis and characterization of target molecules for Wyeth.

About Wyeth

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women’s health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.

Wyeth is one of the world’s largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company’s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

GVK Biosciences, India’s premier Contract Research Organization, delivers integrated research services to big Pharma and Biotech companies globally. The company accelerates the Drug Discovery and Development process of its customers through science and innovation. Currently the company has more than 1,300 employees spread across facilities in Hyderabad, Chennai and Gurgaon.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: Ogilvy Public Relations


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

GVK BIO Inaugurates its New Research Center

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Publisher Contact: Sreekar Reddy - 
+91 98 66110032 sreekar.reddy[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Ogilvy Public Relations securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From Ogilvy Public Relations / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform
Precision Medicine Unlocks the Future of Targeted Therapy in the Global Healthcare Industry Finds Frost & Sullivan
Sciformix Corporation Receives Prestigious 2017 Global Outsourcing Customer Service Leadership Award from Frost & Sullivan
Arven Pharmaceuticals Selects GE Healthcare’s FlexFactory to Improve Turkish and Regional Access to Biopharmaceuticals
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma
Cost-Containment and Client-Centric Services Catalyse European Custom Procedure Trays and Packs Market Finds Frost & Sullivan
New BD Institute for Medication Management Excellence Aims to Improve Patient Safety and Outcomes through Collaboration
New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians
Greenphire and Exostar Partner to Deliver Seamless, Secure Access to Clinical Research Site Payment Solution
PleurX™ Catheter System Receives FDA 510(k) Clearance for Specific Non-Malignant Recurrent Pleural Effusions
First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  NAKIVO, Inc.


  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (